XORTX Therapeutics Inc.(XRTX)Earnings, Financials & Key Ratios
XRTX•NASDAQ
$2.04
Price updated Jul 7, 2026
AboutXORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is based in Vancouver, Canada.Show more
- Revenue$0
- EBITDA-$3M+42.6%
- Net Income-$3M+41.5%
- EPS (Diluted)-14.20+64.1%
- ROE-77.23%+19.7%
XRTX Price & Volume
XORTX Therapeutics Inc. (XRTX) stock price & volume — 10-year historical chart
Loading chart...
Clinical Development Burn Threatens Corporate Liquidity Runway
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent liquidity and dilution
Key Thesis Takeaways
- XORTX Therapeutics remains a high-risk, pre-revenue clinical-stage entity whose survival is entirely contingent upon securing external capital to fund its XRx-008 development program.
- The company's financial trajectory is characterized by persistent operational losses and a rapidly eroding asset base, which has seen total assets contract from $6.1 million in 2024Q1 to $2.2 million by 2026Q1.
- Investors should exercise extreme caution as the current cash position of $251,100 appears insufficient to sustain ongoing R&D requirements, likely necessitating further dilutive financing.
Verdict Logic
the company's precarious liquidity position, evidenced by a cash balance of only $251,100 against ongoing clinical development costs, suggests an imminent risk of significant shareholder dilution.
XRTX Growth Metrics
XORTX Therapeutics Inc. (XRTX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-177.41%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-54.63%
Return on Capital
10 Years-203.69%
5 Years-77.93%
3 Years-89.25%
Last Year-94.66%
Peers Comparison
Key metrics vs top competitors for XORTX Therapeutics Inc. (XRTX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $2.04 | $568.12K | -0.14 | — | — | -77.23% | — | |
| $5.38 | $1.32B | -20.69 | 22.09% | -13.58% | -38.11% | — | |
| $31.49 | $3.85B | 18.74 | 19.78% | 37.08% | 23.65% | — | |
| $368.60 | $10.87B | 53.89 | 33.94% | 53.92% | 19.25% | — | |
| $14.49 | $4.55B | -164.85 | 20.05% | -4.27% | -12.02% | — | |
| $35.87 | $3.53B | -6.15 | 20.13% | -91.03% | — | — |
Compare XRTX vs Peers
XORTX Therapeutics Inc. (XRTX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when XRTX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
XRTX Frequently Asked Questions
XORTX Therapeutics Inc. (XRTX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is XRTX profitable?
XORTX Therapeutics Inc. (XRTX) reported a net loss of $2.8M for fiscal year 2025.
Dividend & Returns
What is XRTX's return on equity?
XORTX Therapeutics Inc. (XRTX) has a return on equity (ROE) of -77.2%. Negative ROE indicates the company is unprofitable.
What is XORTX Therapeutics Inc.'s free cash flow?
XORTX Therapeutics Inc. (XRTX) had negative free cash flow of $2.1M in fiscal year 2025, likely due to heavy capital investments.